Molecular Partners secures CHF 46 million in series B equity financing led by Essex Woodlands Health Ventures
Swiss biotechnology firm Molecular Partners AG announced the closing of a series B equity investment round of CHF 46 million. The investment round was led by Essex Woodlands Health Ventures, a leading venture capital and growth equity firm in the healthcare industry, and included the participation of all existing investors comprising Index Ventures, BB Biotech Ventures, Johnson & Johnson Development Corporation and Endeavour. This increases the total amount raised by Molecular Partners to CHF 64.5 million since 2007.
Lenz & Staehelin advised Molecular Partners in both the series A and series B financing transactions. The team for the series B financing was led by Beat Kühni and included Dominik Kaczmarczyk and Fabiano Menghini.